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ABSTRACT
Background The antiplatelet drug clopidogrel is a
new thienopyridine derivative whose mechanism of
action and chemical structure are similar to those of
ticlopidine. The estimated incidence of ticlopidine-
associated thrombotic thrombocytopenic purpura is
1 per 1600 to 5000 patients treated, whereas no clopid-
ogrel-associated cases were observed among 20,000
closely monitored patients treated in phase 3 clinical
trials and cohort studies. Because of the association
between ticlopidine use and thrombotic thrombocy-
topenic purpura and other adverse effects, clopidogrel
has largely replaced ticlopidine in clinical practice.
More than 3 million patients have received clopido-
grel. We report the clinical and laboratory findings in
11 patients in whom thrombotic thrombocytopenic
purpura developed during or soon after treatment
with clopidogrel.
Methods The 11 patients were identified by active
surveillance by the medical directors of blood banks
(3 patients), hematologists (6), and the manufacturers
of clopidogrel (2).
Results Ten of the 11 patients received clopidogrel
for 14 days or less before the onset of thrombotic
thrombocytopenic purpura. Although 10 of the 11 pa-
tients had a response to plasma exchange, 2 required
20 or more exchanges before clinical improvement
occurred, and 2 had relapses while not receiving clo-
pidogrel. One patient died despite undergoing plas-
ma exchange soon after diagnosis.
Conclusions Thrombotic thrombocytopenic purpu-
ra can occur after the initiation of clopidogrel therapy,
often within the first two weeks of treatment. Physi-
cians should be aware of the possibility of this syn-
drome when initiating clopidogrel treatment. (N Engl
J Med 2000;342:1773-7.)
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HROMBOTIC thrombocytopenic purpu-
ra is a life-threatening, multisystem disease
characterized by thrombocytopenia, micro-
angiopathic hemolytic anemia, fever, neu-
rologic changes, and renal abnormalities.1 Idiopathic
cases occur at a rate of 3.7 per year per million per-
sons, and the mortality rate for promptly treated cas-
es ranges from 10 to 20 percent.2-5 Many drugs have
been associated with the syndrome.6 In cases that have
been investigated, its cause appears to be related to
autoantibodies against a metalloprotease that degrades
T
von Willebrand factor.7-9 Impaired proteolysis of von
Willebrand factor leads to the binding of unusually
large multimers to platelets and results in the platelet
microthrombi that characterize the syndrome. The
presence of IgG autoantibodies against the protease
distinguishes thrombotic thrombocytopenic purpu-
ra from related syndromes, including the hemolytic–
uremic syndrome.7,8
Ticlopidine, an antiplatelet drug, has been associ-
ated with the development of thrombotic thrombo-
cytopenic purpura, with an estimated incidence of
1 case per 1600 to 5000 patients treated.10-13 Clo-
pidogrel is a new antiplatelet drug that has achieved
widespread clinical acceptance because it has a more
favorable safety profile than ticlopidine.14 The two
drugs are structurally related derivatives of thieno-
pyridine, differing only by one carboxymethyl group.
They have short half-lives in the circulation and differ-
ent metabolites.15 The drugs act by blocking an aden-
osine diphosphate–binding site on platelets, which
inhibits the expression of the glycoprotein IIb/IIIa
receptor in the high-affinity configuration that binds
fibrinogen and large multimers of von Willebrand
factor. Because phase 3 clinical trials and studies in-
volving 20,000 closely monitored patients who were
treated with clopidogrel have not reported neutrope-
nia, adverse skin or gastrointestinal effects, or throm-
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botic thrombocytopenic purpura — all of which have
been associated with ticlopidine therapy — clopido-
grel has largely replaced ticlopidine in clinical prac-
tice for the prevention of stroke and thrombosis in
patients who have received coronary-artery stents and
in patients with peripheral vascular disease or acute
cardiac ischemia.16,17
For all new drugs, a comprehensive assessment of
safety requires diligent post-marketing surveillance.
Ticlopidine-associated thrombotic thrombocytopenic
purpura was not widely recognized until seven years
after the drug was approved by the Food and Drug
Administration (FDA), despite its use by several mil-
lion patients.10-13 Since clopidogrel was approved by
the FDA in early 1998, more than 3 million people
have received the drug, and two cases of thrombotic
thrombocytopenic purpura that occurred after clo-
pidogrel use have been reported at medical confer-
ences.18,19 In the current study, we determined the
clinical characteristics, the interval between clopido-
grel treatment and the onset of disease, the response
to treatment, outcomes, and laboratory findings in
11 patients in whom thrombotic thrombocytopenic
purpura developed during or soon after treatment
with clopidogrel.
METHODS
Eleven cases of thrombotic thrombocytopenic purpura among
patients who were treated with clopidogrel were identified be-
tween March 1998 and March 2000 by active surveillance by the
medical directors of blood banks (three patients), hematologists
(six), and a surveillance program overseen by Sanofi–Synthelabo
and Bristol-Myers Squibb, the manufacturers of clopidogrel (two).
Two of these patients have been described previously.18,19 To be
included in the study, a patient had to have previously taken or
still be taking clopidogrel when he or she received a diagnosis of
thrombotic thrombocytopenic purpura on the basis of clinical and
laboratory findings. For most patients, the results of additional
laboratory studies were not available that could be used to distin-
guish thrombotic thrombocytopenic purpura from other disorders
that may be associated with thrombocytopenia and microangio-
pathic hemolysis.7,8
RESULTS
The 11 patients ranged in age from 35 to 70 years
(median, 55) (Table 1). Six patients were women.
Six patients had received clopidogrel for coronary
artery disease, including three patients who received
the drug after the placement of a coronary-artery
stent. Concomitant medications included the cho-
lesterol-lowering drugs atorvastatin and simvastatin
in five patients, two of whom had begun taking the
drug within the three weeks before the onset of
thrombotic thrombocytopenic purpura; long-term
treatment with atenolol in three patients; and long-
term cyclosporine treatment in one patient who had
undergone kidney–pancreas transplantation. Clopid-
ogrel had been used for 3 to 14 days in all but one
patient (Patient 10). Patient 4 had discontinued clo-
pidogrel 3 weeks before the onset of the syndrome,
and thrombotic thrombocytopenic purpura had oc-
curred after 21 days of atorvastatin therapy. The other
10 patients stopped taking clopidogrel when throm-
botic thrombocytopenic purpura began. Only Pa-
tient 2 had received ticlopidine previously, two years
before the onset of the syndrome, and no thrombo-
cytopenia or hemolysis had occurred during the ear-
lier treatment.
Thrombotic thrombocytopenic purpura was man-
ifested by thrombocytopenia and microangiopathic
hemolytic anemia, with or without neurologic chang-
es or renal dysfunction (Table 1). Platelet counts were
less than 20,000 per cubic millimeter in 10 patients,
and hematocrit values were less than 27 percent in
8 patients. Seven patients had neurologic changes,
including disorientation (in two patients), slurred
speech (in two), confusion (in one), aphasia (in one),
and coma (in one). Four patients had renal insuffi-
ciency, characterized by a serum creatinine level of
more than 2.5 mg per deciliter (221 µmol per liter),
including one who was undergoing long-term dial-
ysis after an unsuccessful renal transplantation and
one who was receiving long-term cyclosporine treat-
ment. This last patient, who had undergone kidney–
pancreas transplantation five years earlier, had normal
renal function, but the onset of the syndrome was
manifested by an acute decrease in renal function,
thrombocytopenia, and microangiopathic hemolysis.
A renal biopsy, performed because of concern over
the possibility of kidney rejection in association with
the rising serum creatinine level, revealed platelet mi-
crothrombi. Two patients had evidence of acute liver
injury, with marked elevation of serum aminotrans-
ferase levels.
All patients underwent plasma exchange, with res-
olution of symptoms and laboratory abnormalities oc-
curring after a median of 8 plasma exchanges (range,
1 to 30) in 10 patients. Patient 9 died after four days
of plasma exchange. Patient 1 had a recurrence im-
mediately after undergoing coronary-artery bypass
surgery, 73 days after the diagnosis of thrombotic
thrombocytopenic purpura. He had a second recur-
rence 2 months later, after receiving atorvastatin for
14 days. Each recurrence responded quickly to plas-
ma exchange.19 Patient 10 had three recurrences, the
last occurring seven months after the discontinua-
tion of clopidogrel; each recurrence responded to
plasma exchange. None of the 10 surviving patients
were rechallenged with clopidogrel.
Plasma samples from Patients 1 and 2 were available
for the measurement of von Willebrand factor–cleav-
ing protease activity and the inhibitory activity of IgG,
according to previously published techniques.7 In both
patients, during episodes of thrombotic thrombocy-
topenic purpura, von Willebrand factor–cleaving pro-
tease activity was undetectable and IgG inhibitors of
the protease were present. Concentrations of 3.2 mg
of IgG per milliliter in the case of Patient 1 and of
2.5 mg of IgG per milliliter in the case of Patient 2
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were required to inhibit protease activity by 50 per-
cent in mixtures containing 12 percent plasma from
a normal subject. During remission three months af-
ter plasma exchange, the protease activity in plasma
samples from Patient 2 was 67 percent of the mean
(±SD) value (103±12 percent) in plasma samples
from 57 normal subjects, and at a concentration of
6.6 mg per milliliter, his IgG caused no inhibition of
the protease activity in the mixing assay.
DISCUSSION
We reviewed the clinical and laboratory findings in
11 patients in whom thrombotic thrombocytopenic
purpura developed during or soon after treatment
with clopidogrel. Thrombotic thrombocytopenic pur-
pura can result in multiorgan dysfunction or death.
In our patients, the disease was characterized by the
occurrence of thrombocytopenia, microangiopathic
hemolytic anemia, neurologic changes, and renal dys-
function during treatment with clopidogrel or, in one
patient, soon after treatment was stopped. One pa-
tient died, eight had complete resolution of throm-
botic thrombocytopenic purpura after the discontin-
uation of clopidogrel and treatment with plasma ex-
change, and two had relapses up to seven months
after the onset of the syndrome, with rapid recovery
after plasma exchange.
The features of thrombotic thrombocytopenic pur-
pura in patients who received ticlopidine and in those
who received clopidogrel can be contrasted, despite
marked differences in the methods used to ascertain
cases. First, unlike the cases reported among ticlopi-
dine-treated patients, 95 percent of which occurred
after 2 to 12 weeks of treatment, all but one of the cas-
es among clopidogrel-treated patients occurred with-
in 2 weeks after the initiation of treatment.10-12,21,22
Second, whereas in almost all patients with ticlo-
pidine-associated thrombotic thrombocytopenic pur-
pura who had a response to plasma exchange, the re-
sponse occurred after 7 or fewer plasma exchanges
and there were no relapses,13 two patients in our study
required 20 or more plasma exchanges before the
*Patient 1 has been described previously.19
†Patient 2 has been described previously.18
‡Patient 8 had normal renal function and a one-month history of failing pancreatic function five years after undergoing kidney–pancreas
transplantation. The patient had been receiving cyclosporine for the five years before the onset of thrombotic thrombocytopenic purpura.
§Patient 3 had undergone unsuccessful renal transplantation and was undergoing dialysis before the onset of thrombotic thrombocytopenic
purpura.
¶The severity of disease was assessed with the Rose and Eldor scoring system, which evaluates the platelet count, the hemoglobin level,
the serum creatinine level, and neurologic function.20 Each category is given a score of 0 (normal findings), 1 (mildly abnormal clinical or
laboratory findings), or 2 (markedly abnormal clinical or laboratory findings) on the basis of specific criteria; a total combined score of 4 or
more indicates a diagnosis of severe thrombotic thrombocytopenic purpura. A platelet count of more than 100,000 per cubic millimeter is
assigned a score of 0, a count of 20,000 to 100,000 per cubic millimeter a score of 1, and a count of less than 20,000 per cubic millimeter
a score of 2. A hematocrit value of more than 36 percent is assigned a score of 0, a value of 27 to 36 percent a score of 1, and a value of
less than 27 percent a score of 2. A serum creatinine level of less than 1.5 mg per deciliter (133 mmol per liter) is assigned a score of 0, a
level of 1.5 to 2.5 mg per deciliter a score of 1, and a level of more than 2.5 mg per deciliter a score of 2. A score of 0 is assigned if no
neurologic deficits are present; a score of 1 if confusion, lethargy, or behavioral changes are present; and a score of 2 if a focal deficit, con-
vulsions, stupor, or coma is present.
¿NA denotes not available. Patient 9 died after four days of plasma exchange.

























Age (yr) 55 54 66 61 36 49 49 35 60 65 70
Sex M M F M F F F M F M F
Duration of clopidogrel therapy 
(days)
7 14 14 3 10 8 8 3 5 330 7
Platelet count <20,000/mm3 Yes Yes Yes Yes Yes Yes Yes No Yes Yes Yes
Hematocrit <27 percent No No Yes No Yes Yes Yes Yes Yes Yes Yes
Serum creatinine >2.5 mg/dl 
(221 mmol/liter)
No No Yes§ No No No Yes Yes Yes No No
Neurologic changes Yes No Yes No Yes Yes Yes No Yes Yes No
Rose and Eldor score¶ 3 3 6 2 5 5 7 5 6 6 5
Schistocytes on peripheral-blood 
smear
Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
Serum lactate dehydrogenase 
(U/liter)
2500 933 1765 2349 1239 1100 1645 929 4118 791 235
No. of plasma exchanges 12 30 20 6 6 13 7 4 NA¿ 10 1
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symptoms and laboratory abnormalities resolved, and
two patients had a total of five relapses.
Third, only 57 percent of the previously reported
cases of ticlopidine-associated thrombotic thrombocy-
topenic purpura were treated with plasma exchange,13
as compared with all the cases in our study. Rather
than attributing the clinical symptoms to coronary
procedures or vascular disease, physicians’ heightened
awareness of the possibility of thrombotic thrombo-
cytopenic purpura may have led to early diagnosis
and use of plasma exchange in our patients. Among
patients who were treated with plasma exchange, 18
percent of those with ticlopidine-associated throm-
botic thrombocytopenic purpura died (11 patients),
as compared with 9 percent of our patients with clo-
pidogrel-associated disease (1 patient). Fifty-eight per-
cent of the patients (22) with ticlopidine-associated
thrombotic thrombocytopenic purpura who did not
undergo plasma exchange died.10,13 We have previ-
ously reported that the overall mortality rate for ticlo-
pidine-associated cases was 33 percent, in part due
to lower rates of use of plasma exchange, particularly
in patients older than 60 years of age.10,13
Finally, the use of cholesterol-lowering drugs was
not evaluated in the patients with ticlopidine-associ-
ated cases; almost half the patients with clopidogrel-
associated cases had received cholesterol-lowering
drugs. In one of our patients, thrombotic thrombo-
cytopenic purpura appeared to be induced by ator-
vastatin, and one patient had a recurrence during
treatment with atorvastatin that responded quickly to
plasma exchange.19 One case of thrombotic throm-
bocytopenic purpura has been reported after short-
term treatment with simvastatin.23 The possibility
that cholesterol-lowering drugs and clopidogrel may
have adverse pharmacologic interactions in some pa-
tients deserves further study.
The mechanism by which clopidogrel could cause
thrombotic thrombocytopenic purpura is not known.
Patients with idiopathic7,8 and ticlopidine-associated24
thrombotic thrombocytopenic purpura have an im-
mune-mediated deficiency of von Willebrand fac-
tor–cleaving protease activity in plasma — a finding
that distinguishes this syndrome from the clinically
related hemolytic–uremic syndrome. Laboratory stud-
ies in two of our patients revealed that during the
acute phase of the disease, IgG inhibitors of the pro-
tease were detectable and the plasma was severely
deficient in protease activity. During clinical remis-
sion in one patient, plasma protease activity had in-
creased to a nearly normal level and the patient’s
IgG did not inhibit protease activity. However, it is
premature to conclude on the basis of these findings
that clopidogrel causes an immune reaction to the
protease. The number of cases that have been inves-
tigated is small, and a limited number of plasma
samples from affected patients are available. Further-
more, in some patients the syndrome occurred after
three or five days of clopidogrel treatment, which
makes an antibody-mediated mechanism induced by
clopidogrel seem unlikely. These observations sug-
gest that despite having similar chemical structures,
clopidogrel and ticlopidine may cause thrombotic
thrombocytopenic purpura by different mechanisms.
Unlike ticlopidine, clopidogrel has not been associ-
ated with apoptosis of microvascular endothelial cells
in culture.25
Our findings have important clinical implications.
Clopidogrel has largely replaced ticlopidine in clini-
cal practice.15,16 One of the reasons for this change
was the association of ticlopidine use with throm-
botic thrombocytopenic purpura. Other reasons were
the lower rates of skin, hematologic, and gastrointes-
tinal adverse effects associated with clopidogrel and
its more convenient dosing schedule.14 Our cases of
thrombotic thrombocytopenic purpura after treat-
ment with clopidogrel appear to differ from cases as-
sociated with the use of ticlopidine in that they oc-
curred soon after the initiation of therapy, were prone
to recurrence, and required up to 30 plasma exchang-
es before clinical improvement occurred. The devel-
opment of cardiac or neurologic changes after the
initiation of clopidogrel therapy may be mistakenly
attributed to the underlying condition for which it
was prescribed. Physicians should be aware of the
possibility of thrombotic thrombocytopenic purpu-
ra among patients who are receiving clopidogrel.
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